论文部分内容阅读
目的分析探讨乙型肝炎肝硬化失代偿期运用阿德福韦酯联合拉米夫定治疗的临床效果。方法 78例乙型肝炎肝硬化失代偿期患者,随机分为对照组和观察组,各39例。两组患者均给予对症治疗,此外对照组给予拉米夫定治疗,观察组在对照组基础上给予阿德福韦酯治疗。观察两组患者治疗前后的肝功能指标水平以及乙型肝炎病毒脱氧核糖核酸(HBV-DNA)的水平、转阴率。结果治疗前,两组患者各项肝功能指标水平比较差异无统计学意义(P>0.05);治疗后,两组患者各项肝功能指标均有所改善,且观察组患者改善效果较对照组更为显著,差异具有统计学意义(P<0.05)。治疗前,两组患者HBV-DNA水平比较差异无统计学意义(P>0.05);治疗后,两组患者HBV-DNA水平均较治疗前明显降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组HBV-DNA转阴率为89.74%(35/39),明显高于对照组的69.23%(27/39),差异具有统计学意义(P<0.05)。结论运用阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化失代偿期临床效果良好,能显著恢复患者的各项肝功能指标,具有重要的临床价值,值得推广。
Objective To investigate the clinical effect of adefovir dipivoxil combined with lamivudine in the treatment of decompensated cirrhosis of hepatitis B patients. Methods 78 patients with decompensated hepatitis B cirrhosis were randomly divided into control group and observation group, 39 cases in each group. Two groups of patients were given symptomatic treatment, in addition to the control group given lamivudine treatment, the observation group on the basis of the control group given adefovir dipivoxil treatment. The levels of liver function index and the level of hepatitis B virus DNA (HBV-DNA) and the rate of negative conversion before and after treatment in both groups were observed. Results Before treatment, there was no significant difference in the indexes of liver function between the two groups (P> 0.05). After treatment, the indexes of liver function of both groups improved, and the improvement effect of the observation group was better than that of the control group More significant, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in HBV-DNA levels between the two groups (P> 0.05). After treatment, the HBV-DNA levels in both groups were significantly lower than those before treatment, and the observation group was lower than the control group Significance (P <0.05). After treatment, the negative rate of HBV-DNA in the observation group was 89.74% (35/39), which was significantly higher than that in the control group (69.23%, 27/39). The difference was statistically significant (P <0.05). Conclusion Adefovir dipivoxil combined with lamivudine treatment of hepatitis B cirrhosis decompensated good clinical results, can significantly restore the patient’s various liver function indicators, has important clinical value, it is worth promoting.